Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DMAC vs INBX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAC Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 4–2 Matrix Metrics)

DMAC Overall Winner 6-Pillar Tally: DMAC 4 – 0 INBX (2 Tie) Matrix Metrics: DMAC 4 – 2 INBX

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Inhibrx Biosciences, Inc. (INBX) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DMAC carries a Unified Composite Score of 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin), whereas INBX carries 49.8/100 (HOLD) at $77.32 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While INBX currently prints a higher short-term Unified Composite Score (49.8/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (4–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 46.0); meanwhile INBX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DMAC vs INBX
DMAC NASDAQ Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 98% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.0 · SMA20: $9.24 · SMA50: $8.24
INBX NASDAQ
Inhibrx Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$77.32
-7.18% 1D
Market Cap $1.3B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.53β · 120% Vol
Unified Composite Score
49.8 / 100 HOLD
Tech 48.0 Fund 54.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.0%), weak momentum, RSI 41
RSI-14: 40.6 · SMA20: $85.66 · SMA50: $94.39

6-Pillar Scorecard Institutional Category Breakdown (DMAC 4 – 0 INBX)

Columns: Metric · DMAC · INBX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale DMAC
Revenue Growth (YoY) +0.0% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $503.1M $1.3B
3. Profitability & Quality DMAC
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -114.6% -1773.6%
4. Balance Sheet & Cash Flow DMAC
Cash Generation (TTM) -$32M -$132M
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.9M Net Cash $48M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DMAC
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 106.3% (14th %ile) 116.5% (8th %ile)
Put/Call OI Skew N/A 0.71x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DMAC (4) vs INBX (2)
Institutional Metric DMAC INBX Criterion Row Edge
Market Capitalization
Scale
$503.1M $1.3B Larger Scale INBX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -100.0% Higher Growth DMAC
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-114.6% -1773.6% Higher ROE DMAC
52-Week Range Position
Momentum
55% ($5–$11) 20% ($57–$155) Stronger Trend DMAC
Beta / 30D Volatility
Risk Regime
1.74β · 98% Vol 2.53β · 120% Vol Lower Realized Risk DMAC
Unified Institutional Score
Composite Signal
46.3 / 100 (HOLD) 49.8 / 100 (HOLD) Higher Composite INBX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$32M ($4.9M Net Cash) -$132M ($48M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DMAC +25.09 pp
DMAC: +11.16% · INBX: -13.93%
3M Horizon DMAC +45.6 pp
DMAC: +27.31% · INBX: -18.29%
6M Horizon DMAC +75.07 pp
DMAC: +48.15% · INBX: -26.92%
1Y Horizon DMAC +51.65 pp
DMAC: +55.26% · INBX: +3.61%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DMAC Revenue INBX Revenue DMAC Op. Margin INBX Op. Margin Margin Leader
FY2018 $0M N/A -1352.2% N/A DMAC
FY2023 N/A $0M N/A -12178.9% INBX
FY2024 N/A $0M N/A -165724.0% INBX
FY2025 N/A $0M N/A -10386.5% INBX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INBX BREAKDOWN
134d in phase · OBV DISTRIBUTION
Current IV 116.5%
IV Percentile 8th %ile
Put/Call OI Skew 0.71x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact INBX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
INBX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DMAC vs INBX Key Questions & Quantitative Answers

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Inhibrx Biosciences, Inc. (INBX) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DMAC carries a Unified Composite Score of 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin), whereas INBX carries 49.8/100 (HOLD) at $77.32 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While INBX currently prints a higher short-term Unified Composite Score (49.8/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (4–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY). Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 46.0); meanwhile INBX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DMAC leads the Growth & Scale pillar: DMAC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with INBX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 4-period historical trajectory (FY2018 to FY2025), DMAC cumulative revenue shifted N/A while INBX shifted N/A. In operating R&D and SG&A reinvestment, DMAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for INBX.

DMAC and INBX trade at balanced relative valuation multiples. DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas INBX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DMAC (-114.6% ROE) versus INBX (-1773.6% ROE) capital efficiency.

In options market volatility and institutional positioning, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk). By comparison, INBX carries 116.5% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.71x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.53β · 120% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.